John Bencich
2021
In 2021, John Bencich earned a total compensation of $1.6M as Chief Executive Officer at OncoGenex Pharmaceuticals, a 82% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $302,250 |
|---|---|
| Option Awards | $648,283 |
| Salary | $465,000 |
| Stock Awards | $196,350 |
| Total | $1,611,883 |
Bencich received $648.3K in option awards, accounting for 40% of the total pay in 2021.
Bencich also received $302.3K in non-equity incentive plan, $465K in salary and $196.4K in stock awards.
Rankings
In 2021, John Bencich's compensation ranked 6,941st out of 12,415 executives tracked by ExecPay. In other words, Bencich earned more than 44.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,941 out of 12,415 | 44th |
Division Manufacturing | 3,035 out of 5,508 | 45th |
Major group Chemicals And Allied Products | 1,345 out of 2,378 | 43rd |
Industry group Drugs | 1,200 out of 2,099 | 43rd |
Industry In Vitro and In Vivo Diagnostic Substances | 26 out of 61 | 57th |
Source: SEC filing on April 21, 2022.
Bencich's colleagues
We found two more compensation records of executives who worked with John Bencich at OncoGenex Pharmaceuticals in 2021.
News
OncoGenex Pharmaceuticals CEO John Bencich's 2022 pay slips 7% to $1.5M
April 28, 2023
OncoGenex Pharmaceuticals CEO John Bencich's 2021 pay jumps 82% to $1.6M
April 21, 2022
OncoGenex Pharmaceuticals CEO Richard Stewart's 2020 pay jumps 30% to $1M
March 30, 2021
OncoGenex Pharmaceuticals CEO Richard Stewart's 2019 pay falls 27% to $797K
April 2, 2020
OncoGenex Pharmaceuticals CEO Richard Stewart's 2018 pay jumps 423% to $1.1M
March 28, 2019